surface antigen

DRUG2 trials

Sponsors

Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Cr2o B.V.

Conditions

COVID-19 and fluInfluenza

Phase 2

CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER

CompletedCTIS2024-514798-23-00

Cr2o B.V.COVID-19 and flu

Start: 2024-10-02End: 2025-03-04Target: 120Updated: 2024-10-14

Phase 4

Optimizing the time of day of influenza vaccine administration in adults aged 60-85 years: A randomized controlled trial

CompletedCTIS2024-513558-30-00

Rijksinstituut voor Volksgezondheid en Milieu (RIVM)Influenza

Start: 2024-09-25End: 2025-05-01Target: 440Updated: 2024-09-12